AAMI Updates Standard for Manufacturers of Medtech Steam Sterilization Systems
Arlington, Virginia--(Newsfile Corp. - July 14, 2026) - The Association for the Advancement of Medical Instrumentation (AAMI) today announces the revision to its American National Standard that establishes safety and performance requirements for steam sterilization units used to process reusable medical devices in hospitals and other healthcare delivery organizations.
2026-07-14 8:55 AM EDT | Association for the Advancement of Medical Instrumentation
QScreen AI Secures Second US Patent, Extending Single-Camera Impairment Detection on Standard Hardware
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection method, after the United States Patent and Trademark Office granted the Company US Patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026. The new grant extends the Company's protection to impairment detection from a single came
2026-07-14 7:02 AM EDT | QScreen AI Inc.
TelyRx Expands Operations in Clearwater, Fla., Tripling Footprint to Meet Growing Demand for Digital Healthcare
Clearwater, Florida--(Newsfile Corp. - July 14, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a digital healthcare and online pharmacy platform, today announced a major expansion of its Clearwater headquarters and pharmacy operations, following the milestone of one million prescriptions filled and first-quarter revenue growth of 180% year-over-year. The move more than triples TelyRx's overall footprint to meet growing consumer
Soins de santé et hôpitaux, Santé
2026-07-14 7:00 AM EDT | TelyRx
Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a strategic operational update regarding its collaboration with the Richardson Centre for Food Technology and Research (RCFTR) at the University of Manitoba. Following the recent unveiling of its newly formulated product roadmap, targeted to capitalize on emerging consumer shopping patterns, the Comp
Technologies, Biotechnologies, Santé
2026-07-14 6:00 AM EDT | Restart Life Sciences Corp.
Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ
Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition.
Soins de santé et hôpitaux, Santé
2026-07-13 9:00 AM EDT | Adia Med Inc.
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor me
2026-07-13 8:00 AM EDT | BetterLife Pharma Inc.
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.
Biotechnologies, Pharmaceutique, Santé
2026-07-13 8:00 AM EDT | BioHarvest Sciences Inc.
Glow Lifetech Advances National Expansion Strategy with Quebec Commercial Partnership
Toronto, Ontario--(Newsfile Corp. - July 13, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce it has entered into an exclusive Quebec sales, distribution and licensing agreement with Les Cultures Seaweed Gaspésie Inc. ("Seaweed Cannabis"), establishing the commercial infrastructure to support the commercialization of Glow's MOD™ and .decimal™ brands in Quebec. The partnership represents another im
2026-07-13 7:30 AM EDT | Glow Lifetech Corp.
Rejuvenate Muscle Health(TM) Expands its Position in the Emerging GLP-1 Muscle Health Category with U.S. Pharmacy Program and National E-Commerce Expansion
Burlington, Ontario--(Newsfile Corp. - July 13, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") a muscle health company with distributi
Aliments / boissons, Sports, Santé
2026-07-13 7:00 AM EDT | Promino Nutritional Sciences, Inc.
WELL Health Announces Pricing of $150 Million Senior Unsecured Notes Offering
WELL has priced its inaugural offering of $150 million of senior unsecured notes due 2031, bearing interest at 6.875% per annum. Net proceeds will be used to fully repay WELL's convertible debentures due December 2026 and for general corporate purposes. The Offering extends WELL's debt maturity profile to 2031 and strengthens the Company's balance sheet to support continued growth in Canada. All amounts in
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-07-13 6:30 AM EDT | WELL Health Technologies Corp.
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - July 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company issued common shares ("Common Shares") in satisfaction of the accrued interest payable on June 30, 2026. The Notes were issued as a result of an extension to the promissory notes th
2026-07-10 7:13 PM EDT | Rapid Dose Therapeutics Corp.
NU-Med Plus Announces Acquisition of Avid Gold and Agreement to Acquire Canadian Gold Properties
United Kingdom and Vancouver, British Columbia--(Newsfile Corp. - July 10, 2026) - Nu-Med Plus, Inc. (OTCQB: NUMD) ("Nu-Med" or the "Company"), a Utah company whose shares are quoted on the OTCQB Venture Market, today announces that it has acquired Avid Gold Ltd ("Avid Gold") and its wholly-owned subsidiary Maritimes Gold Corp. ("Maritimes Gold"), a Canadian gold exploration and development company. The Company also announced today that Nu-Med and its subsidia
2026-07-10 4:15 PM EDT | Nu-Med Plus, Inc.
TelyRx Holdings Inc. Announces DTC Eligibility for U.S. Traded Shares
Clearwater, Florida--(Newsfile Corp. - July 10, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a digital healthcare and online pharmacy platform, today announced that its subordinate voting shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company ("DTC"). DTC eligibility is expected to simplify trading, improvement settlement efficiency, and enhance the liquidity a
Soins de santé et hôpitaux, Santé
2026-07-10 7:00 AM EDT | TelyRx
DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx(TM) Red Eye and Quantitative ELISA Testing
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx™ Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating
2026-07-09 8:30 AM EDT | DiagnosTear Technologies Inc.
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee. Mr. LaRocca is a three-decade biopharmaceutical in
2026-07-09 8:00 AM EDT | BetterLife Pharma Inc.
Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review
Winter Park, Florida--(Newsfile Corp. - July 9, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) announced today that FINRA has processed its corporate name change to Adia Med Inc. on an expedited timeline. The name change will be reflected on the FINRA Daily List today, with trading under the new name expected to begin tomorrow, Friday, July 10, 2026, on the OTC Markets.
Soins de santé et hôpitaux, Santé
2026-07-09 8:00 AM EDT | Adia Med Inc.
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Highlights Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel's four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-09 7:00 AM EDT | TempraMed Technologies Ltd.
Rise Nano Optics Announces First U.S. Eye Care Professional Partnership with LI Opticians
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced its first U.S. eye care professional (ECP) partnership with LI Opticians, an independent optical practice located in Seaford, New York, owned and operated by Barry Santini, a contributing editor to Lenses & Technolo
2026-07-09 12:15 AM EDT | Rise Nano Optics Ltd.
TelyRx to Present at the Global Technology Virtual Investor Conference July 9, 2026
Clearwater, Florida--(Newsfile Corp. - July 8, 2026) - Hot on the heels of its one million prescriptions filled milestone, TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and online pharmacy platform focused on expanding access to FDA-approved medications across the United States, announced today that Vanessa Slowey, President and Chief Executive Officer, and John Cascio, Chief Financial Officer, will present live at t
Soins de santé et hôpitaux, Santé
2026-07-08 1:05 PM EDT | TelyRx
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Biotechnologies, Pharmaceutique, Santé
2026-07-08 10:08 AM EDT | Hemostemix Inc.